Targeted screening for detection and monitoring
Accurately detect benzodiazepine use
Benzodiazepines represent a large family of medications used to treat a wide range of disorders, from anxiety to seizures. They also are used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with many benzodiazepines.
Mayo Clinic Laboratories now offers a targeted, high-resolution mass spectrometry screening assay that will identify 27 different benzodiazepines and metabolites in the urine, and reduces the need for additional confirmation assays. Results of this assay will enable clinicians to accurately detect recent benzodiazepine use and effectively monitor treatment compliance.
Targeted screening for enhanced detection
TBSU | Targeted Benzodiazepine Screen, Random, Urine
Ensure adherence to federal and state regulations by:
Substances assessed include, but are not limited to:
Comprehensive monitoring profiles
TABSU | Targeted Benzodiazepine Screen, Random, Urine
Profiles which include TABSU
New high-resolution targeted benzodiazepine screen
Paul Jannetto, Ph.D., highlights Mayo Clinic’s new targeted benzodiazepine assay, and discusses the advantages and limitations of various urine screening assays and quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Analysis of urine drug testing results by our experts, who apply the most up-to-date scientific data, enables further transparency and clear answers that illuminate patients’ drug use.
Pharmacokinetics of CNS depressants
Substances that can interfere with simple (immunoassay) CNS depressants screening results